CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Australas J Dermatol
; 64(2): 194-203, 2023 May.
Article
en En
| MEDLINE
| ID: mdl-36892928
ABSTRACT
The CD30-postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T-cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Papulosis Linfomatoide
/
Trastornos Linfoproliferativos
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
País/Región como asunto:
Oceania
Idioma:
En
Revista:
Australas J Dermatol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Australia